Page last updated: 2024-12-06

2,2'-dipyridyl disulfide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,2'-Dipyridyl disulfide, also known as DPDS, is a heterocyclic disulfide compound used as a reagent in organic synthesis and has been investigated for its potential biological activities. It is synthesized by oxidizing 2,2'-dipyridyl with hydrogen peroxide or other oxidizing agents. DPDS exhibits strong oxidizing properties and is known to react with thiols, forming mixed disulfides. This property has led to its application in the synthesis of peptides and proteins. DPDS has been studied for its potential as an antimicrobial agent, showing activity against various bacteria and fungi. Further research has investigated its potential in treating cancer and other diseases. It is believed that DPDS might act as a redox modulator, influencing the balance of reactive oxygen species (ROS) in cells. Its effects on cellular signaling pathways are also under investigation. The potential of DPDS in these areas has driven ongoing research to further understand its properties and applications.'

2,2'-dipyridyl disulfide: disulfide is an important moiety in this cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aldrithiol : A member of the class of pyridines that is pyridine which is substituted by a pyridin-2-yldisulfanediyl group at position 2. It is a reagent used in molecular biology as an oxidizing agent. Also used in peptide synthesis and for detecting thiols. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65093
CHEMBL ID118678
CHEBI ID143170
SCHEMBL ID21174
MeSH IDM0041197

Synonyms (108)

Synonym
smr000473199
MLS001143364 ,
AC-4591
2-pyridin-2-yldisulfanylpyridine
aldrithiol 2
pyridine, 2,2'-dithiobis-
aldrithiol-2
nsc-677438
2,2'-dipyridyldisulfide
2,2'-dithiopyridine
pyridine,2'-dithiobis-
2,2'-dithiobispyridine
2,2'-dipyridyl disulfide
bis(2-pyridinyl) disulfide
nsc94055
di-2-pyridyl disulfide
2pds
pyridine,2'-dithiodi-
2-dipyridyl disulfide
di(2-pyridyl) disulfide
nsc-94055
bis(2-pyridyl) disulfide
nsc677438
aldrithiol(tm)-2
2,2'-dithiodipyridine
2127-03-9
2-(2-pyridyldisulfanyl)pyridine
2,2'-dithiodipyridine, powder
aldrithiol(tm)-2, 98%
D1114
NCIOPEN2_006257
2,2'-diithiodipyridine
haxfwiacagnfha-uhfffaoysa-
inchi=1/c10h8n2s2/c1-3-7-11-9(5-1)13-14-10-6-2-4-8-12-10/h1-8h
2-(pyridin-2-yldisulfanyl)pyridine
CHEMBL118678
AKOS002248740
bis(2-pyridyl)disulfide
2,2'-dithiobis(pyridine)
2,2'-disulfanediyldipyridine
aldrithiol
2,2'-pyridine disulfide
2-pyridinyl disulfide
2,2'-dipyridyldisulphide
di(2-pyridyl)disulfide
2,2'-dithiobis-pyridine
CHEBI:143170
HMS2805F21
A26592
2-(2-pyridinyldisulfanyl)pyridine;2,2'-dipyridinyl disulfide
orthopyridyl disulfide
2,2 inverted exclamation marka-dipyridyl disulfide
unii-l6x912upbu
nsc 94055
nsc 677438
pyridine, 2,2'-dithiodi-
einecs 218-343-1
l6x912upbu ,
STL220574
BP-20233
FT-0609299
1,2-di(pyridin-2-yl)disulfane
c10h8n2s2
SCHEMBL21174
dithiodipyridine
aldrithioltm-2
2-pyridyldisulfide
1,2-bis(pyridin-2-yl)disulfane
2.2'-dipyridyl disulfide
1,2-di(pyridine-2-yl)disulfane
pyridyl disulfide
2-pyridyl-disulfide
dipyridyldisulfide
2,2'-dipyridyl-disulfide
di(pyridin-2-yl) disulfide
2-,2'-dipyridyl disulfide
pyridyldisulfide
2-pyridyl disulfide
di(pyridin-2-yl)disulfide
dipyridyl disulphide
2-(2-(pyridin-2-yl)disulfanyl)pyridine
dipyridyl disulfide
aldrithol-2
2,2'-dipyridinyl disulfide
2-(2-pyridinyldisulfanyl)pyridine #
cid_65093
2-(2-pyridinyldisulfanyl)pyridine
bdbm60840
Q-101297
mfcd00006287
DTXSID70175517
pyridine, dithiobis-
CS-W008788
2,2'-dithiodipyridine, >=99.0% (gc)
Q4596740
BP-23823
AS-13979
AMY23184
BBL100074
bis(pyridin-2-yl) disulfide
di-2-pyridinyl disulfide; di-2-pyridyl disulfide; nsc 677438; nsc 94055
2,2-dithiodipyridine
opss
opssorthopyridyl disulfide
2,2'-dithiodipyridine?
1,2-di(pyridin-2-yl)disulfide
HY-Y1666
EN300-172822

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Of all tested reagents, organic mercury compounds arose as the most toxic reagents."( Hepatotoxic effects of SH-reagents in human and rat hepatocyte cultures and in situ perfused rat livers.
Boot, JH, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
oxidising agentA substance that removes electrons from another reactant in a redox reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organic disulfideCompounds of structure RSSR in which R and R' are organic groups.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency3.98110.631035.7641100.0000AID504339
WRNHomo sapiens (human)Potency22.38720.168331.2583100.0000AID651768
GLS proteinHomo sapiens (human)Potency10.00000.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency3.76010.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency22.38720.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency39.81070.707912.194339.8107AID720542
hypothetical protein, conservedTrypanosoma bruceiPotency25.11890.223911.245135.4813AID624173
regulator of G-protein signaling 4Homo sapiens (human)Potency56.23410.531815.435837.6858AID504845
IDH1Homo sapiens (human)Potency25.92900.005210.865235.4813AID686970
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency3.16230.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency11.22020.006026.168889.1251AID540317
flap endonuclease 1Homo sapiens (human)Potency89.12510.133725.412989.1251AID588795
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency0.67020.168316.404067.0158AID720504
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency22.38720.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency15.70190.004611.374133.4983AID624296; AID624297
VprHuman immunodeficiency virus 1Potency44.66841.584919.626463.0957AID651644
Glycoprotein hormones alpha chainHomo sapiens (human)Potency10.00004.46688.344810.0000AID624291
TAR DNA-binding protein 43Homo sapiens (human)Potency12.58931.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonasePlasmodium bergheiIC50 (µMol)44.90670.889021.028671.5000AID504765; AID540252; AID540269
glucose-6-phosphate 1-dehydrogenase isoform bHomo sapiens (human)IC50 (µMol)80.00008.870012.851817.8000AID504792
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)3.88000.270026.3638100.0000AID504719
DNA dC->dU-editing enzyme APOBEC-3A isoform aHomo sapiens (human)IC50 (µMol)100.00001.480014.526761.2000AID504722
Histone-lysine N-methyltransferase EHMT2Homo sapiens (human)IC50 (µMol)0.65000.00251.14809.2000AID1374899
Histone-lysine N-methyltransferase EHMT1Homo sapiens (human)IC50 (µMol)2.70000.01300.79954.9000AID1374900
large T antigenBetapolyomavirus macacaeIC50 (µMol)100.00000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
MSRA proteinBos taurus (cattle)EC50 (µMol)103.87903.63704.05004.4630AID623963
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (57)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to starvationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of DNA replicationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
synaptonemal complex assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
spermatid developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
long-term memoryHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
fertilizationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of protein modification processHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
organ growthHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
phenotypic switchingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to ethanolHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
behavioral response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
oocyte developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
neuron fate specificationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to xenobiotic stimulusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of autophagosome assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine monomethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
regulation of embryonic developmentHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
enzyme bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K56 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
promoter-specific chromatin bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nuclear speckHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nuclear bodyHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1374899Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1631058Antiviral activity against HIV1 infected in HEK293T cells at 1 mM after 1 hr by luciferase reporter gene assay relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631053Antiviral activity against GFP-transducing HIV1 infected in HEK293T cells at 1 mM after 1 hr by GFP fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID89802Inhibition of HIV-1 replication in a proliferating human T-cell line assayed using an XTT assay.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors.
AID1374896Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374902Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374897Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374898Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374901Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID89654Inhibition of HIV-1 replication in human T-cell by using XTT assay; Inactive1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors.
AID1374895Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374900Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (131)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (19.85)18.7374
1990's32 (24.43)18.2507
2000's41 (31.30)29.6817
2010's26 (19.85)24.3611
2020's6 (4.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.98 (24.57)
Research Supply Index4.91 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.74%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other134 (99.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]